Drugs / ACTR T Cell Product
ACTR T Cell Product
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03680560 | Mar 2019 → Mar 2020 | neoplasm | Cogent Biosciences, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACTR T Cell Product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03680560 ↗ |
| Known as | ACTR087 | “Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)” NCT03680560 ↗ |
| Known as | ACTR707 | “Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)” NCT03680560 ↗ |
| Modality | Cell therapy | “Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product” NCT03680560 ↗ |